|Articles|February 4, 2009
Spectral domain OCT for drusen evaluation
Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration
Advertisement
Please click
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery
2
From skepticism to clarity and focus: A family’s PRESBYOND experience
3
Celltrion’s EYLEA-referencing biosimilar, EYDENZELT, receives Canadian approval
4
Evolving Practice In Retinal Care A Question Of Control
5











































